Sigma Planning Corp’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-92,500
| Closed | -$2.23M | – | 1381 |
|
|
2023
Q1 | $2.23M | Sell |
92,500
-61,290
| -40% | -$769K | 0.07% | 273 |
|
|
2022
Q4 | $1.63M | Buy |
153,790
+100
| +0.1% | +$807 | 0.06% | 334 |
|
|
2022
Q3 | $692K | Hold |
153,690
| – | – | 0.03% | 599 |
|
|
2022
Q2 | $615K | Buy |
153,690
+28,070
| +22% | +$133K | 0.02% | 673 |
|
|
2022
Q1 | $920K | Buy |
125,620
+3,625
| +3% | +$21.7K | 0.03% | 570 |
|
|
2021
Q4 | $686K | Buy |
121,995
+1,650
| +1% | +$10.5K | 0.02% | 699 |
|
|
2021
Q3 | $770K | Buy |
120,345
+9,880
| +9% | +$63.5K | 0.02% | 639 |
|
|
2021
Q2 | $931K | Buy |
110,465
+25,130
| +29% | +$203K | 0.03% | 581 |
|
|
2021
Q1 | $896K | Buy |
85,335
+26,245
| +44% | +$369K | 0.03% | 545 |
|
|
2020
Q4 | $1M | Buy |
59,090
+450
| +0.8% | +$6.75K | 0.03% | 433 |
|
|
2020
Q3 | $752K | Sell |
58,640
-400
| -0.7% | -$5.05K | 0.03% | 477 |
|
|
2020
Q2 | $833K | Sell |
59,040
-17,840
| -23% | -$225K | 0.04% | 437 |
|
|
2020
Q1 | $707K | Sell |
76,880
-3,505
| -4% | -$45.2K | 0.04% | 399 |
|
|
2019
Q4 | $1.2M | Buy |
80,385
+11,485
| +17% | +$102K | 0.05% | 357 |
|
|
2019
Q3 | $470K | Buy |
68,900
+10,950
| +19% | +$111K | 0.02% | 597 |
|
|
2019
Q2 | $701K | Buy |
+57,950
| New | +$315K | 0.04% | 448 |
|
Other funds holding PRVB
Sigma Planning Corp's PRVB Position: Q2 2023 in Review
Sigma Planning Corp sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 92,500 shares — an estimated $2.23M sold.
Sigma Planning Corp first reported a position in PRVB in Q2 2019 and held it in 16 quarters. The position peaked at $2.23M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Sigma Planning Corp reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Sigma Planning Corp sold 92,500 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $2.23M.
- Sigma Planning Corp first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- Sigma Planning Corp's Provention Bio, Inc. Common Stock position peaked at $2.23M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Sigma Planning Corp's 13F filing for Q2 2023, filed 2 Aug 2023.